Soligenix, inc. announces adjournment of annual meeting, information for reconvened annual meeting

Princeton, n.j. , oct. 20, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 annual meeting of stockholders (the "annual meeting"), which was reconvened on october 18, 2023, has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the company's definitive proxy statement for the annual meeting filed with the securities and exchange commission (the "sec") on august 7, 2023, as supplemented on september 15, 2023 and september 22, 2023.
SNGX Ratings Summary
SNGX Quant Ranking